Stefanie Marti

Bern, BE, Switzerland

Last Updated: 09/26/2026

Save publications for later

Sign Up

Not sure about your diagnosis?

Check Your Symptoms

Found 12 publications

BrainAgeMS: protocol for a prospective comparative study of brain aging in healthy adults and people with multiple sclerosis.

BrainAgeMS: protocol for a prospective comparative study of brain aging in healthy adults and people with multiple sclerosis.

Journal: Frontiers in neurology

Published: June 04, 2026

Higher disease reactivation risk in women after fingolimod withdrawal.

Higher disease reactivation risk in women after fingolimod withdrawal.

Journal: Acta neuropathologica communications

Published: March 17, 2026

Dissecting definitions of disability accrual in relapsing multiple sclerosis-Have we reached standardization yet?

Dissecting definitions of disability accrual in relapsing multiple sclerosis-Have we reached standardization yet?

Journal: Multiple sclerosis (Houndmills, Basingstoke, England)

Published: December 06, 2025

Field strength-dependent sensitivity of chemical exchange saturation transfer: a methodological comparison of 3 Tesla and 7 Tesla in a clinical cohort.

Field strength-dependent sensitivity of chemical exchange saturation transfer: a methodological comparison of 3 Tesla and 7 Tesla in a clinical cohort.

Journal: Brain communications

Published: July 25, 2025

Extracellular Vesicle Marker Changes Associated With Disease Activity in Relapsing-Remitting Multiple Sclerosis.

Extracellular Vesicle Marker Changes Associated With Disease Activity in Relapsing-Remitting Multiple Sclerosis.

Journal: Neurology(R) neuroimmunology & neuroinflammation

Published: April 29, 2025

Inequalities in access to industry-funded interventional phase I-IV drug trials in epilepsy.

Inequalities in access to industry-funded interventional phase I-IV drug trials in epilepsy.

Journal: Epilepsia open

Published: March 10, 2025

Increased vision impairment reports linked to semaglutide: analysis of FDA adverse event data.

Increased vision impairment reports linked to semaglutide: analysis of FDA adverse event data.

Journal: BMC medicine

Published: August 22, 2024

Disability progression is a question of definition-A methodological reappraisal by example of primary progressive multiple sclerosis.

Disability progression is a question of definition-A methodological reappraisal by example of primary progressive multiple sclerosis.

Journal: Multiple sclerosis and related disorders

Published: June 14, 2024

Socioeconomic and Regional Disparities in Industry-Sponsored Clinical Trials in Multiple Sclerosis.

Socioeconomic and Regional Disparities in Industry-Sponsored Clinical Trials in Multiple Sclerosis.

Journal: JAMA network open

Published: November 29, 2023

Sex differences in multiple sclerosis relapse presentation and outcome: a retrospective, monocentric study of 134 relapse events.

Sex differences in multiple sclerosis relapse presentation and outcome: a retrospective, monocentric study of 134 relapse events.

Journal: Therapeutic advances in neurological disorders

Published: September 14, 2023

Different lymphocyte counts of multiple sclerosis patients treated with ofatumumab and ocrelizumab: A retrospective observational study.

Different lymphocyte counts of multiple sclerosis patients treated with ofatumumab and ocrelizumab: A retrospective observational study.

Journal: Journal of central nervous system disease

Published: July 14, 2023

The impact of immunotherapies on COVID-19 case fatality rates during the US vaccination campaign: a multidisciplinary open data analysis using FDA Adverse Event Reporting System and Our World in Data.

The impact of immunotherapies on COVID-19 case fatality rates during the US vaccination campaign: a multidisciplinary open data analysis using FDA Adverse Event Reporting System and Our World in Data.

Journal: Frontiers in pharmacology

Published: March 16, 2023

Showing 1-12 of 12

Last Updated: 09/26/2026